Targeting histone deacetylases in neuroblastoma

Current Pharmaceutical Design

Volumn 15, Issue 4, 2009, Pages 436-447

  Witt, O ^a   Deubzer, H E ^a   Lodrini, M ^a   Milde, T ^a   Oehme, I ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Drug targets; Epigenetics; HDAC; HDAC inhibitor; Histone Deacetylase; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 4 PHENYLBUTYRIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BL 1521; BUTYRIC ACID; DEPSIPEPTIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HKI 46F 08; MYCN PROTEIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; ONCOPROTEIN; RETINOIC ACID; ROMIDEPSIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ENZYME INHIBITOR;

ACETYLATION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD CELL COUNT; CANCER STAGING; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CHEMOSENSITIVITY; CLINICAL TRIAL; DISEASE MODEL; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ELECTROCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; EPIGENETICS; FATIGUE; GASTROINTESTINAL DISEASE; GENE REPRESSION; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; MOLECULAR MECHANICS; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; T CELL LYMPHOMA; THROMBOCYTOPENIA; UPREGULATION; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM;

ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEUROBLASTOMA;

EID: 64249143717     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787315774     Document Type: Review

References (87)

1. Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978; 14: 105-13.
2. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 17174-9.
3. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996; 272: 408-11.
4. Witt O, Deubzer H, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2008; [Epub ahead of print].
5. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
6. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90.
7. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003; 370: 737-49.
8. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31.
9. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
10. Wade PA, Pruss D, Wolffe AP. Histone acetylation: Chromatin in action. Trends Biochem Sci 1997; 22: 128-32.
11. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008; 9: 206-18.
12. Huang Y, Myers SJ, Dingledine R. Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nat Neurosci 1999; 2: 867-72.
13. Ahringer J. NuRD and SIN3 histone deacetylase complexes in development. Trends Genet 2000; 16: 351-6.
14. Wen YD, Perissi V, Staszewski LM, Yang WM, Krones A, Glass CK, et al. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc Natl Acad Sci USA 2000; 97: 7202-7.
15. Atsumi A, Tomita A, Kiyoi H, Naoe T. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun 2006; 345: 1471-80.
16. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, et al. ETO, a target of t(8; 21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 2001; 21: 6470-83.
17. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 2000; 408: 106-11.
18. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 2004; 24: 8374-85.
19. Chang S, Bezprozvannaya S, Li S, Olson EN. An expression screen reveals modulators of class II histone deacetylase phosphorylation. Proc Natl Acad Sci USA 2005; 102: 8120-5.
20. Berdeaux R, Goebel N, Banaszynski L, Takemori H, Wandless T, Shelton GD, et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat Med 2007; 13: 597-603.
21. Kim MA, Kim HJ, Brown AL, Lee MY, Bae YS, Park JI, et al. Identification of novel substrates for human checkpoint kinase Chk1 and Chk2 through genome-wide screening using a consensus Chk phosphorylation motif. Exp Mol Med 2007; 39: 205-12.
22. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417: 455-8.
23. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601-7.
24. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981-9.
25. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
26. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000; 408: 377-81.
27. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006; 38: 566-9.
28. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009; in press:
29. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 2007; 99: 1107-19.
30. Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY, et al. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci USA 2007; 104: 18682-7.
31. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis. Lancet Oncol 2008; 9: 139-48.
32. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001; 92: 1300-4.
33. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: Correlation with poor prognosis with possible regulation. Pancreas 2008; 36: E1-9.
34. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98: 604-10.
35. Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 2007; 72: 69-74
36. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188-93.
37. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
38. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409: 581-9.
39. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62: 4916-21.
40. Deubzer HE, Ehemann V, Kulozik AE, Westermann F, Savelyeva L, Kopp-Schneider A, et al. Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro. Cancer Lett 2008;
41. Deubzer HE, Ehemann V, Westermann F, Heinrich R, Mechtersheimer G, Kulozik AE, et al. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer 2008; 122: 1891-900.
42. de Ruijter AJ, Kemp S, Kramer G, Meinsma RJ, Kaufmann JO, Caron HN, et al. The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells. Biochem Pharmacol 2004; 68: 1279-88.
43. Ouwehand K, de Ruijter AJ, van Bree C, Caron HN, van Kuilenburg AB. Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins. FEBS Lett 2005; 579: 1523-8.
44. Wegener D, Hildmann C, Riester D, Schober A, Meyer-Almes FJ, Deubzer HE, et al. Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay. Biochem J 2008; 413: 143-50.
45. Wegener D, Deubzer HE, Oehme I, Milde T, Hildmann C, Schwienhorst A, et al. HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. Anticancer Drugs 2008; 19: 849-57.
46. Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007; 17: 2874-8.
47. Cinatl J, Jr., Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, et al. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 1996; 7: 766-73.
48. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-78.
49. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999; 59: 4392-9.
50. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62: 6108-15.
51. De los Santos M, Zambrano A, Aranda A. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther 2007; 6: 1425-32.
52. De los Santos M, Zambrano A, Sanchez-Pacheco A, Aranda A. Histone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and post-transcriptional mechanisms. Mol Endocrinol 2007; 21: 2416-26.
53. Coffey DC, Kutko MC, Glick RD, Swendeman SL, Butler L, Rifkind R, et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 2000; 35: 577-81.
54. Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, et al. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci USA 2008; 105: 9751-6.
55. Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, Fruhwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007; 120: 1787-94.
56. Muhlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM, et al. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. BMC Cancer 2006; 6: 214.
57. Michaelis M, Suhan T, Cinatl J, Driever PH, Cinatl J, Jr. Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol 2004; 25: 1795-9.
58. Kuljaca S, Liu T, Tee AE, Haber M, Norris MD, Dwarte T, et al. Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Mol Cancer 2007; 6: 68.
59. Muhlethaler-Mottet A, Meier R, Flahaut M, Bourloud KB, Nardou K, Joseph JM, et al. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 2008; 7: 55.
60. Haecker S, Debatin K, Fulda S. Histone deacetylase inhibitors overcome TRAIL resistance in cancers with epigenetic silencing of caspase-8 by restoring caspase-8 expression [abstract]. Annual Meeting of the AACR: 2008; San Diego, CA 2008; Abstract nr 1562:
61. de Ruijter AJ, Leen R, Hoebink J, Caron HN, van Kuilenburg AB. Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells. Cancer Lett 2006; 233: 240-6.
62. Sonnemann J, Kumar KS, Heesch S, Muller C, Hartwig C, Maass M, et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 2006; 28: 755-66.
63. Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F, et al. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 2005; 13: 1139-44.
64. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 1241-6
65. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95: 6791-6.
66. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008; 153: 657-68.
67. Stockhausen MT, Sjolund J, Manetopoulos C, Axelson H. Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer 2005; 92: 751-9.
68. Politis PK, Akrivou S, Hurel C, Papadodima O, Matsas R. BM88/Cend1 is involved in histone deacetylase inhibition-mediated growth arrest and differentiation of neuroblastoma cells. FEBS Lett 2008; 582: 741-8.
69. Subramanian C, Opipari AW, Jr., Bian X, Castle VP, Kwok RP. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 4842-7.
70. Subramanian C, Jarzembowski JA, Opipari AW, Jr., Castle VP, Kwok RP. CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A. Neoplasia 2007; 9: 495-503.
71. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 2008; 8: 132-40.
72. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001; 61: 1477-85.
73. Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M, et al. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 2003; 66: 897-906.
74. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 2002; 91: 837-44.
75. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002; 21: 427-36.
76. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004; 65: 520-7.
77. Cinatl J, Jr., Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: Enhancement by combination with interferon-alpha. Int J Oncol 2002; 20: 97-106.
78. Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007; 67: 1716-24.
79. Cinatl J, Jr., Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B, et al. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 1997; 8: 958-63.
80. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 2001; 61: 3591-4.
81. Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006; 12: 223-34.
82. Witt O, Schweigerer L, Driever PH, Wolff J, Pekrun A. Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 2004; 43: 181.
83. Fouladi M, Furman WL, Chin T, Freeman BB, 3rd, Dudkin L, Stewart CF, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: A Children's Oncology Group report. J Clin Oncol 2006; 24: 3678-85.
84. Fouladi M, Park J, Sun J, Fraga C, Ames MM, Stewart CF, et al. A phase I trial of vorinostat in children with refractory solid tumors: A Children's Oncology Group Study. Abstract ASCO07L_34327 2007.
85. Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 2008; 14(6): 505-28.
86. Itoh Y, Suzuki T, Miyata N. Isoform-selective histone deacetylase inhibitors. Curr Pharm Des 2008; 14(6): 529-44.
87. Jones P, Steinkuhler C. From natural products to small molecule ketone histone deacetylase inhibitors: Development of new class specific agents. Curr Pharm Des 2008; 14(6): 545-61.